Intel stock spikes after report of possible US government stake
FREDERICK, Md. - TOMI Environmental Solutions, Inc. (NASDAQ:TOMZ), a small-cap company with a market value of $18.82 million, has completed the first installation of its new SteraMist Integration System Standalone (SIS-SA) in the pharmaceutical isolator market, the company announced Wednesday. InvestingPro data shows the company maintains a healthy liquidity position with a current ratio of 2.25, indicating strong ability to meet short-term obligations.
The installation was implemented at a leading pharmaceutical drug Contract Development and Manufacturing Organization (CDMO) that had previously purchased several Surface Unit handheld direct spray systems from TOMI in 2023. The CDMO acquired the SIS-SA with a 90-degree applicator earlier this year to retrofit an existing isolator in collaboration with a prominent isolator manufacturing company.
The SIS-SA is part of the SteraMist Integrated Systems product line launched in the second half of last year. The system uses the company’s ionized Hydrogen Peroxide (iHP) technology for disinfection and decontamination.
"The successful installation of our first SIS-SA system marks an important achievement and is a milestone in our strategy to expand our footprint in the life sciences industry," said Dr. Halden Shane, CEO and Chairman of TOMI Environmental Solutions.
According to the company, the life science sterility testing market is projected to grow to $3.4 billion by 2031 at a compound annual growth rate of 12.4%. TOMI expects to generate over $500,000 in revenue from the new SIS-SA product in fiscal 2025.
The company reports that additional SIS-SA installations are scheduled for later this year.
TOMI’s Binary Ionization Technology platform was initially developed under a defense grant in association with the Defense Advanced Research Projects Agency of the U.S. Department of Defense.
This article is based on information from a company press release.
In other recent news, TOMI Environmental Solutions reported a significant year-over-year increase in net revenue for the first quarter of 2025, reaching approximately $1.6 million, up from $1.1 million in the same quarter the previous year. Despite this revenue growth, the company posted a net loss of $0.3 million, or $0.01 per share, although this was an improvement from a net loss of $1.3 million, or $0.07 per share, in the first quarter of 2024. The company’s gross margin for the quarter was recorded at 60.4%, slightly below the previous year’s average. TOMI also announced the appointment of David Vanston as its new Chief Financial Officer, bringing over 25 years of financial leadership experience to the company. Meanwhile, H.C. Wainwright analyst Amit Dayal maintained a Buy rating on the company’s stock, reflecting confidence in its financial results and recent fundraising efforts. Additionally, TOMI’s SteraMist technology has shown promise in combating the Deformed Wing Virus, a major contributor to honeybee colony collapse, according to a study by the USDA. The company continues to focus on product innovation and strategic partnerships to enhance its market presence.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.